Compare · BIAF vs SLGC
BIAF vs SLGC
Side-by-side comparison of bioAffinity Technologies Inc. (BIAF) and SomaLogic Inc. (SLGC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIAF and SLGC operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- SLGC is the larger of the two at $1.43B, about 199.1x BIAF ($7.2M).
- BIAF has hit the wire 5 times in the past 4 weeks while SLGC has been quiet.
- SLGC has more recent analyst coverage (6 ratings vs 0 for BIAF).
- Company
- bioAffinity Technologies Inc.
- SomaLogic Inc.
- Price
- $1.62-5.81%
- $2.09-5.43%
- Market cap
- $7.2M
- $1.43B
- 1M return
- -23.58%
- -
- 1Y return
- -81.28%
- -
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2022
- 2021
- News (4w)
- 5
- 0
- Recent ratings
- 0
- 6
Latest BIAF
- bioAffinity Technologies Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Multidisciplinary Physician Panel to Share Real-World Benefits of bioAffinity Technologies' Noninvasive CyPath Lung Cancer Test in Upcoming Society for Advanced Bronchoscopy Webinar
- bioAffinity Technologies Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- bioAffinity Technologies Announces Notification of Mexico Patent Allowance Covering Novel Lung Cancer Detection Methods Using CyPath® Lung Technology
- SEC Form S-8 filed by bioAffinity Technologies Inc.
- SEC Form 424B3 filed by bioAffinity Technologies Inc.
- SEC Form EFFECT filed by bioAffinity Technologies Inc.
- bioAffinity Technologies Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- bioAffinity Technologies Reports Record Monthly CyPath® Lung Unit Sales and Significant Year-Over-Year Growth in April 2026
- bioAffinity Technologies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest SLGC
- OncoHost Selected to Present in Oral Minisymposium at American Association of Cancer Research (AACR) Annual Meeting 2024
- SEC Form SC 13G/A filed by SomaLogic Inc. (Amendment)
- SEC Form SC 13G/A filed by SomaLogic Inc. (Amendment)
- SEC Form 15-12G filed by SomaLogic Inc.
- SEC Form EFFECT filed by SomaLogic Inc.
- SEC Form EFFECT filed by SomaLogic Inc.
- Taich Adam returned 48,425 shares to the company, closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Ryan Jason
- Roelke Alison Marie returned 17,143 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Post Richard A returned 57,430 shares to the company, closing all direct ownership in the company (SEC Form 4)